WALTHAM, Mass.--(BUSINESS WIRE)--Glytec, the pioneer and leader in providing innovative, FDA-cleared glucose management software solutions central to effective diabetes management, announced today that Hartford HealthCare will deploy the company’s eGlycemic Management System® (eGMS®) across its five hospitals. eGMS® enables providers, payers and patients to control glucose levels and combat the well-documented, spiraling complications and costs associated with diabetes and hyperglycemia.
Hartford HealthCare (HHC), well known for quality, complex and innovative care, consists of Hartford Hospital, Backus Hospital, MidState Medical Center, The Hospital of Central Connecticut and Windham Hospital, as well as numerous clinics throughout Connecticut. Glytec’s unique eGMS® will help support HHC’s tradition of patient focus and quality of care by providing access to evidence-based, medical intelligence for patients requiring insulin therapy.
“Glycemic management has long been a priority for our health system, and our results have historically been very good. Our previous efforts have included deploying our own IV insulin dosing decision support tool on a limited basis, but the complexity and costs associated with maintaining and scaling the tool, as well as attempting to add subcutaneous dosing support with the necessary integrations and analytics, were challenging,” said Dr. Rocco Orlando III, senior vice president and chief medical officer, Hartford HealthCare. “We conducted an extensive review of potential alternatives and selected Glytec because it provides a truly comprehensive system — one that will enable us to standardize our approach across all our hospitals and areas of care.”
eGMS® provides clinician-developed, algorithm-based software (Glucommander™) designed to consider insulin sensitivity, and provide individualized dosing recommendations to address and prevent excursions through all aspects of insulin therapy – including intravenous (IV), transition from IV to subcutaneous (SubQ), SubQ, and pediatric dosing recommendations. The ongoing performance and impact of HHC’s glycemic control initiative will be measured and monitored through Glytec’s GlucoMetrics®. Additionally, GlucoSurveillance® will provide near real-time identification of patients in need of glycemic intervention and insulin therapy.
The eGMS® will be integrated with HHC’s Cerner and Epic EMRs to allow for a seamless end-user experience. Through the standardization of processes and personalization of treatment, eGMS® has been proven to reduce infection rates, length-of-stay, readmissions and resource utilization (clinician time as well as supplies).
“Glytec is collaborating with healthcare providers across the country to establish a new standard of care in glycemic control. Partnering with HHC, a leader in patient care and itself a pioneer in the glycemic management realm, is a natural fit,” said Melanie Mabrey, DNP, ACNP-BC, BC-ADM, CDTC, FAANP, vice president of clinical practice, Glytec. “HHC is equally passionate about achieving the best diabetes care possible and we couldn't be more excited about adding them to our growing list of health system clients and the impact our relationship will have on their patients.”
About Hartford HealthCare
Hartford HealthCare is Connecticut’s most comprehensive healthcare network. Our fully integrated health system includes a tertiary-care teaching hospital, an acute-care community teaching hospital, an acute-care hospital and trauma center, two community hospitals, the state’s most extensive behavioral health services network, a statewide clinical laboratory operation, a large primary care physician practice group, a regional home care system, an array of senior care services, a coordinated cancer institute with five cancer centers, and a large physical therapy rehabilitation network. To learn more, visit www.hartfordhealthcare.org, and see how Hartford HealthCare is creating a better future for healthcare in Connecticut and beyond.
Founded in 2006, Glytec is a rapidly growing digital heath company specializing in advanced technology for diabetes management. eGMS®, Glytec’s glycemic management information system, enables providers, payers and patients to significantly reduce the frequency, risks and costs of hyperglycemia and hypoglycemia. The cloud based, modular eGMS® centers on the Glucommander™ Suite of FDA-cleared, predictive dosing algorithms for IV, subcutaneous and pediatric dosing: Glucommander™ IV (FDA clearance 2006), Glucommander™ SubQ (FDA clearance 2010) and Glucommander™ Pediatrics (FDA clearance 2012). Comprehensive management of patients requiring insulin therapy is further enabled by seamless EHR integration (SmartClick®) and robust analytics (GlucoMetrics®) and surveillance (GlucoSurveillance®) capabilities. The unique breadth and depth of the eGMS® interventional clinical decision support tools allows providers to standardize processes and individualize treatment across all areas of care, and is proven to result in significant improvements in clinical and financial outcomes versus traditional methods. For more information, please visit http://www.glytecsystems.com.